Literature DB >> 24566180

N-acylated derivatives of sulfamethoxazole and sulfafurazole inhibit intracellular growth of Chlamydia trachomatis.

Sania Marwaha1, Hanna Uvell, Olli Salin, Anders E G Lindgren, Jim Silver, Mikael Elofsson, Asa Gylfe.   

Abstract

Antibacterial compounds with novel modes of action are needed for management of bacterial infections. Here we describe a high-content screen of 9,800 compounds identifying acylated sulfonamides as novel growth inhibitors of the sexually transmitted pathogen Chlamydia trachomatis. The effect was bactericidal and distinct from that of sulfonamide antibiotics, as para-aminobenzoic acid did not reduce efficacy. Chemical inhibitors play an important role in Chlamydia research as probes of potential targets and as drug development starting points.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24566180      PMCID： PMC3993265          DOI： 10.1128/AAC.02015-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  High content screening applied to large-scale cell biology.

Authors:  Vivek C Abraham; D Lansing Taylor; Jeffrey R Haskins
Journal:  Trends Biotechnol       Date:  2004-01       Impact factor: 19.536

3.  A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.

Authors:  Sandra Muschiol; Leslie Bailey; Asa Gylfe; Charlotta Sundin; Kjell Hultenby; Sven Bergström; Mikael Elofsson; Hans Wolf-Watz; Staffan Normark; Birgitta Henriques-Normark
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

4.  Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.

Authors:  Leslie Bailey; Asa Gylfe; Charlotta Sundin; Sandra Muschiol; Mikael Elofsson; Peter Nordström; Birgitta Henriques-Normark; Raimond Lugert; Anders Waldenström; Hans Wolf-Watz; Sven Bergström
Journal:  FEBS Lett       Date:  2007-01-17       Impact factor: 4.124

5.  Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.

Authors:  K Wolf; H J Betts; B Chellas-Géry; S Hower; C N Linton; K A Fields
Journal:  Mol Microbiol       Date:  2006-09       Impact factor: 3.501

6.  Antimicrobial activity of several antibiotics and a sulfonamide against Chlamydia trachomatis organisms in cell culture.

Authors:  C C Kuo; S P Wang; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

Review 7.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.

Authors:  Patrik Engström; Bidong D Nguyen; Johan Normark; Ingela Nilsson; Robert J Bastidas; Asa Gylfe; Mikael Elofsson; Kenneth A Fields; Raphael H Valdivia; Hans Wolf-Watz; Sven Bergström
Journal:  J Bacteriol       Date:  2013-07-12       Impact factor: 3.490

9.  Activity of trimethoprim-sulfamethoxazole against Chlamydia trachomatis in vitro.

Authors:  M R Hammerschlag
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

10.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441
View more
  10 in total

1.  N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF.

Authors:  Sergio A Mojica; Olli Salin; Robert J Bastidas; Naresh Sunduru; Mattias Hedenström; C David Andersson; Carlos Núñez-Otero; Patrik Engström; Raphael H Valdivia; Mikael Elofsson; Åsa Gylfe
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis.

Authors:  Elina Hakala; Leena Hanski; Hanna Uvell; Teijo Yrjönen; Heikki Vuorela; Mikael Elofsson; Pia Maarit Vuorela
Journal:  J Antibiot (Tokyo)       Date:  2015-05-06       Impact factor: 2.649

3.  A 2-pyridone amide inhibitor of transcriptional activity in Chlamydia trachomatis.

Authors:  Carlos Núñez-Otero; Wael Bahnan; Katarina Vielfort; Jim Silver; Pardeep Singh; Haitham Elbir; Fredrik Almqvist; Sven Bergström; Åsa Gylfe
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

4.  Modified Fluoroquinolones as Antimicrobial Compounds Targeting Chlamydia trachomatis.

Authors:  Thi Huyen Vu; Erika Adhel; Katarina Vielfort; Ngûyet-Thanh Ha Duong; Guillaume Anquetin; Katy Jeannot; Philippe Verbeke; Sofia Hjalmar; Åsa Gylfe; Nawal Serradji
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

5.  A High-throughput, High-content, Liquid-based C. elegans Pathosystem.

Authors:  Quinton L Anderson; Alexey V Revtovich; Natalia V Kirienko
Journal:  J Vis Exp       Date:  2018-07-01       Impact factor: 1.355

6.  Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation.

Authors:  Leena Hanski; Natalja Genina; Hanna Uvell; Kristina Malinovskaja; Åsa Gylfe; Timo Laaksonen; Ruzica Kolakovic; Ermei Mäkilä; Jarno Salonen; Jouni Hirvonen; Mikael Elofsson; Niklas Sandler; Pia M Vuorela
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

7.  Inhibitory Activity of Pyrroloisoxazolidine Derivatives against Chlamydia trachomatis.

Authors:  Min Ni; Shunxin Xu; Ziyi Liu; Yin Xue; Wenxia Xie; Shengju Yang; Lingyan Liu; Xiaofeng Bao
Journal:  Biomed Res Int       Date:  2021-03-13       Impact factor: 3.411

8.  Synthesis and Biological Evaluation of Arylamide Sulphonate Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 and -3 Inhibitors.

Authors:  Saif Ullah; Julie Pelletier; Jean Sévigny; Jamshed Iqbal
Journal:  ACS Omega       Date:  2022-07-19

9.  Evaluating the Antibiotic Susceptibility of Chlamydia - New Approaches for in Vitro Assays.

Authors:  Hanna Marti; Nicole Borel; Deborah Dean; Cory A Leonard
Journal:  Front Microbiol       Date:  2018-07-03       Impact factor: 5.640

10.  Methyl sulfonamide substituents improve the pharmacokinetic properties of bicyclic 2-pyridone based Chlamydia trachomatis inhibitors.

Authors:  Martina Kulén; Carlos Núñez-Otero; Andrew G Cairns; Jim Silver; Anders E G Lindgren; Emma Wede; Pardeep Singh; Katarina Vielfort; Wael Bahnan; James A D Good; Richard Svensson; Sven Bergström; Åsa Gylfe; Fredrik Almqvist
Journal:  Medchemcomm       Date:  2019-10-17       Impact factor: 3.597
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.